Jump Financial’s Black Diamond Therapeutics BDTX Stock Holding History

Jump Financial’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-39,026	Closed	-$94.8K	–	1907
2025 Q4	$94.8K	Buy	+39,026	New	+$138K	﹤0.01%	1828
2025 Q3	–	Sell	-13,065	Closed	-$32.4K	–	1786
2025 Q2	$32.4K	Buy	+13,065	New	+$25.2K	﹤0.01%	1701
2024 Q2	–	Sell	-38,468	Closed	-$195K	–	1810
2024 Q1	$195K	Sell	38,468 -420	-1%	-$1.69K	0.01%	1691
2023 Q4	$109K	Buy	38,888 +27,616	+245%	+$64.8K	﹤0.01%	1653
2023 Q3	$32.4K	Buy	+11,272	New	+$41.5K	﹤0.01%	1768
2022 Q2	–	Sell	-11,899	Closed	-$33K	–	1620
2022 Q1	$33K	Sell	11,899 -27,401	-70%	-$100K	﹤0.01%	1483
2021 Q4	$209K	Buy	+39,300	New	+$275K	0.01%	1092
2021 Q3	–	Sell	-21,024	Closed	-$256K	–	1106
2021 Q2	$256K	Buy	+21,024	New	+$416K	0.02%	738

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Jump Financial's BDTX Position: Q1 2026 in Review

Jump Financial sold out of Black Diamond Therapeutics (BDTX) in Q1 2026, closing a stake of 39,026 shares — an estimated $94.8K sold.

Jump Financial first reported a position in BDTX in Q2 2021 and held it in 8 quarters. The position peaked at $256K in Q2 2021. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

Jump Financial reported no remaining Black Diamond Therapeutics position as of Q1 2026 after selling out during the quarter.
Jump Financial sold 39,026 Black Diamond Therapeutics shares in Q1 2026, an estimated $94.8K.
Jump Financial first reported a position in Black Diamond Therapeutics in Q2 2021 and held it in 8 quarters.
Jump Financial's Black Diamond Therapeutics position peaked at $256K in Q2 2021.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.